ClinicalTrials.gg
CompletedNCT03427814Updated Oct 26, 2024Results posted

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

A Phase 2 interventional study of Pamiparib and Placebo in Advanced or Inoperable Gastric Cancer, sponsored by BeiGene. Completed at 65 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,186 studies in Stomach Neoplasms with a site in China — 482 open to participants now, 559 under way, 50 of them phase 3. Stomach Neoplasms · China.

Enrollment
330th of 883
136 · median 87
Started
2018
with 57 others
Phase 2
323 of 1,186
133 open now
Registered
311th of 1,186
by date

Among the 1,186 studies in Stomach Neoplasms with a site in China, this one is the 330th largest by enrollment of the 883 interventional ones that give a count, is one of 58 that started in 2018, is one of 323 in phase 2, and was the 311th registered.

Stomach Neoplasms

3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

482 of the 1,186 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

477 more — sign in →

All 482 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,186 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.

Read the detailed description

This is a double-blind, placebo controlled, randomized multicenter global phase 2 study comparing the efficacy and safety of single agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo as maintenance therapy in participants with advanced gastric cancer who have responded to first line platinum based chemotherapy. Participants are randomized 1:1 to BGB-290 (Arm A) or placebo (Arm B). Randomization will be stratified by geography, biomarker status, and ECOG performance status.

Participants will undergo tumor assessments at screening and then every 8 weeks, or as clinically indicated. Administration of BGB-290 or placebo will continue until disease progression, unacceptable toxicity, death, or another discontinuation criterion is met.

After end of treatment, long-term follow-up assessments include tumor imaging every 8 weeks for those participants without disease progression, survival status, and new anticancer therapy.

03

Conditions studied

  • Advanced or Inoperable Gastric Cancer

Browse trials for

Keywords

  • BGB-290
  • PARP inhibitor
  • Phase 2
  • maintenance therapy
  • gastric cancer
  • oral treatment
  • PARALLEL 303
  • PARALLEL
  • BGB290303
  • BGB-290-303
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Signed .
  3. confirmed inoperable locally advanced or adenocarcinoma of the stomach or gastroesophageal junction.
  4. Received platinum based chemotherapy for ≤ 28 weeks.
  5. Confirmed partial response (PR) maintained for ≥ 4 weeks or complete response (CR).
  6. Able to be randomized to study ≤ 8 weeks after last platinum dose.
  7. (ECOG) performance status ≤ 1.
  8. Adequate hematologic, renal and hepatic function.
  9. Must be able to provide for central biomarker assessment.
  10. Females of and non-sterile males must agree to use highly effective methods of throughout the course of study and at least up to 6 months after last dosing.

Key Exclusion Criteria:

  1. Unresolved acute effects of prior therapy ≥ Grade 2.
  2. Prior treatment with PARP inhibitor.
  3. Chemotherapy, biologic therapy, immunotherapy or other anticancer therapy ≤ 14 days prior to randomization.
  4. Major surgery or significant injury ≤ 2 weeks prior to start of study treatment.
  5. Diagnosis of myelodysplastic syndrome (MDS)
  6. Other diagnoses of significant
  7. or
  8. Inability to swallow capsules or disease affecting gastrointestinal function.
  9. Active infections requiring systemic treatment.
  10. cardiovascular disease
  11. Pregnant or nursing females.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Pamiparib

    Participants received pamiparib orally.

    Drug: Pamiparib

  • Placebo comparator
    Placebo

    Participants received placebo orally.

    Drug: Placebo

Interventions

  • 60 mg orally twice daily

    Also known as: BGB-290

  • DrugPlacebo

    60 mg orally twice daily

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Investigator Assessment

    PFS is defined as the time from randomization to progressive disease (PD) per Response Evaluation Criteria in Solid Tumors ( RECIST) Version 1.1 by investigator assessment or death due to any cause, whichever occurs first.

    Time frame: Approximately 23 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Approximately 23 months

  2. Time To Second Subsequent Treatment (TSST)

    TSST is defined as the time from randomization until the second subsequent anticancer therapy or death after next-line therapy

    Time frame: Approximately 23 months

  3. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with a best overall response of Complete Response or Partial Response per RECIST Version 1.1 by investigator assessment

    Time frame: Approximately 23 months

  4. Duration of Response (DOR)

    DOR is defined as the time from the first documented confirmed response of Complete Response or Partial Response to progressive disease (PD) per RECIST Version 1.1 by investigator assessment or death due to any cause, whichever occurs first

    Time frame: Approximately 23 months

  5. Time To Response

    Time to response is defined as the time from randomization to the first documented response of Complete Response or Partial Response per RECIST Version 1.1 by investigator assessment

    Time frame: Approximately 23 months

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From start of study treatment until 30 days after the last study drug intake or initiation of new anticancer therapy, whichever occurs first (up to approximately 4 years and 5.5 months)

07

Results

Posted Sep 21, 2023

Participant flow

Participants were enrolled in multiple study centers in Asia, Australia, Europe, and North America.

Participant flow — Overall Study
MilestonePamiparibPlacebo
Started7165
Completed00
Not completed7165
Withdrew: Withdrawal by subject44
Withdrew: Lost to follow-up02
Withdrew: Death4231
Withdrew: Sponsor's decision10
Withdrew: Investigator's decision12
Withdrew: Disease progression10
Withdrew: Treatment completed01
Withdrew: Sponsor's decision to end study2125
Withdrew: Transfer to long term extension study10

Outcome measures

PrimaryProgression Free Survival (PFS) by Investigator Assessment

PFS is defined as the time from randomization to progressive disease (PD) per Response Evaluation Criteria in Solid Tumors ( RECIST) Version 1.1 by investigator assessment or death due to any cause, whichever occurs first.

Time frame:
Approximately 23 months
Reported as:
Median · Months
Progression Free Survival (PFS) by Investigator Assessment
MonthsPamiparibPlacebo
Progression Free Survival (PFS) by Investigator Assessment3.7 (1.94 to 5.26)2.1 (1.87 to 3.75)
Statistical analysis
  • Pamiparib vs Placebo · Log Rank · p = = 0.1428The one-sided p-value was based on a stratified log-rank test.
SecondaryOverall Survival (OS)

OS is defined as the time from randomization to death due to any cause.

Time frame:
Approximately 23 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPamiparibPlacebo
Overall Survival (OS)10.2 (8.71 to 16.33)12.0 (8.21 to NA)
SecondaryTime To Second Subsequent Treatment (TSST)

TSST is defined as the time from randomization until the second subsequent anticancer therapy or death after next-line therapy

Time frame:
Approximately 23 months
Reported as:
Median · Months
Time To Second Subsequent Treatment (TSST)
MonthsPamiparibPlacebo
Time To Second Subsequent Treatment (TSST)9.8 (8.05 to 10.94)9.7 (7.49 to 14.00)
SecondaryObjective Response Rate (ORR)

ORR is defined as the percentage of participants with a best overall response of Complete Response or Partial Response per RECIST Version 1.1 by investigator assessment

Time frame:
Approximately 23 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsPamiparibPlacebo
Objective Response Rate (ORR)7.7 (1.62 to 20.87)6.3 (0.77 to 20.81)
SecondaryDuration of Response (DOR)

DOR is defined as the time from the first documented confirmed response of Complete Response or Partial Response to progressive disease (PD) per RECIST Version 1.1 by investigator assessment or death due to any cause, whichever occurs first

Time frame:
Approximately 23 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPamiparibPlacebo
Duration of Response (DOR)3.6 (3.48 to NA)NA (5.55 to NA)
SecondaryTime To Response

Time to response is defined as the time from randomization to the first documented response of Complete Response or Partial Response per RECIST Version 1.1 by investigator assessment

Time frame:
Approximately 23 months
Reported as:
Median · Months
Time To Response
MonthsPamiparibPlacebo
Time To Response3.68 (1.8 to 7.3)1.87 (1.87 to 1.9)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From start of study treatment until 30 days after the last study drug intake or initiation of new anticancer therapy, whichever occurs first (up to approximately 4 years and 5.5 months)
Reported as:
Number · Number of participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Number of participantsPamiparibPlacebo
Participants With At Least 1 TEAE6661
Participants with Serious TEAEs1711

Adverse events

Collected over From start of study treatment until 30 days after the last study drug intake or initiation of new anticancer therapy, whichever occurs first (up to approximately 4 years and 5.5 months). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pamiparib42/71 (59.2%)17/71 (23.9%)65/71 (91.5%)
Placebo31/65 (47.7%)11/65 (16.9%)57/65 (87.7%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPamiparibPlacebo
DysphagiaGastrointestinal disorders0/713/65
AnaemiaBlood and lymphatic system disorders3/711/65
Obstruction gastricGastrointestinal disorders0/712/65
VomitingGastrointestinal disorders2/710/65
DeathGeneral disorders2/710/65
PneumoniaInfections and infestations2/711/65
Gastrointestinal haemorrhageGastrointestinal disorders0/711/65
Malignant dysphagiaGastrointestinal disorders0/711/65
Upper gastrointestinal haemorrhageGastrointestinal disorders1/711/65
SepsisInfections and infestations0/711/65
Most frequent other events
Showing 10 of 59
Most frequent other events
EventPamiparibPlacebo
AnaemiaBlood and lymphatic system disorders25/7110/65
NauseaGastrointestinal disorders23/7112/65
Decreased appetiteMetabolism and nutrition disorders19/719/65
VomitingGastrointestinal disorders16/712/65
AstheniaGeneral disorders16/7112/65
Abdominal painGastrointestinal disorders9/7113/65
DiarrhoeaGastrointestinal disorders13/719/65
Abdominal pain upperGastrointestinal disorders12/717/65
ConstipationGastrointestinal disorders9/719/65
Peripheral sensory neuropathyNervous system disorders4/719/65

Baseline characteristics

Intent to Treat (ITT) Analysis Set included all randomized participants who were assigned to a study drug (pamiparib or placebo)

Age, Continuous
Age, Continuous(years)PamiparibPlaceboTotal
Mean62.5 ± 9.8262.1 ± 11.2362.3 ± 10.48
Sex: Female, Male
Sex: Female, Male(Participants)PamiparibPlaceboTotal
Female252045
Male464591
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PamiparibPlaceboTotal
Hispanic or Latino459
Not Hispanic or Latino5350103
Unknown or Not Reported141024
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PamiparibPlaceboTotal
Asian201535
Black or African America022
Native Hawaiian or Other Pacific Islander011
White383674
Other134
Not Reported/Unknown12820
08

Study locations

65 sites
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Scri Florida Cancer Specialist East
    West Palm Beach, Florida 33401, United States
  • Goshen Center For Cancer Care
    Goshen, Indiana 46526, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40217, United States
  • Novant Health Hematology Charlotte
    Charlotte, North Carolina 28204, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Gosford Hospital
    Gosford, New South Wales 2250, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Ballarat Oncology and Haematology Services
    Wendouree, Victoria 3355, Australia
  • St John of God Health Care
    Subiaco, Western Australia 6008, Australia
  • Az Sint Jan Brugge
    Brugge, 8000, Belgium
  • University Hospitals Leuven
    Leuven, 3000, Belgium
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Sun Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515031, China
  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • The Affiliated Hospital of Qingdao University Branch South
    Qingdao, Shandong 266000, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai 200032, China
  • Fakultni Nemocnice Bulovka
    Praha, 18081, Czechia
  • Chru de Brest Hospital Morvan
    Brest, 29200, France
  • Chu Besancon Hopital Jean Minjoz
    Doubs, 25030, France
  • Hopital Prive Jean Mermoz
    Lyon, 69008, France
  • Icm Val Daurelle Oncologie Medicale
    Montpellier, 24298, France
  • Hopital Prive Des Cotes Darmor Service Oncologie
    Plerin, 22190, France
  • Centre Eugene Marquis
    Rennes, 35043, France
  • Ico Site Rene Gauducheau
    SaintHerblain, 44805, France
  • Iuc Toulouse Oncopole
    Toulouse, 31059, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Acad Fridon Todua Medical Center Ltd Research Institute of Clinical Medicine Ltd
    Tbilisi, 0112, Georgia
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Orszagos Onkologiai Intezet
    Budapest, 1122, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pecs, H-7624, Hungary
  • Nho Kyushu Cancer Center
    Fukuokashi, Fukuoka 811-1395, Japan
  • Kindai University Nara Hospital
    Ikoma, Nara 630-0293, Japan
  • Oita University Hospital
    Yufushi, Oita 879-5593, Japan
  • Kindai University Hospital
    Osakasayama, Osaka 589-8511, Japan
  • Osaka University Hospital
    Suitashi, Osaka 565-0871, Japan
  • Saitama Medical University International Medical Center
    Hidakashi, Saitama 350-1298, Japan
  • Showa University Koto Toyosu Hospital Oncology
    Koto, Tokyo 135-8577, Japan
  • Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
    Gdynia, 81-519, Poland
  • Centrum Onkologii Ziemi Lubelskiej
    Lublin, 20-090, Poland
  • Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy
    Warszawa, 02-034, Poland
  • Mazowiecki Szpital Onkologiczny
    Wieliszew, 05-135, Poland
  • Arkhangelsk Regional Clinical Oncological Dispensary
    Arkhangelsk, Arkhangel'skaya Oblast' 163045, Russian Federation
  • Regional Buz Kurskiy Regional Clinical Oncologic Dispensary
    Kursk, Kurskaya Oblast' 305035, Russian Federation
  • Bih of Omsk Region Clinical Oncology Dispensary
    Omsk, Omskaya Oblast' 644013, Russian Federation
  • Pavlov First Saint Petersburg State Medical University
    SaintPetersburg, Sankt-Peterburg 197022, Russian Federation
  • State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary
    Volgograd, Volgogradskaya Oblast' 400138, Russian Federation
  • Tan Tock Seng Hospital Oncology
    Singapore, 308433, Singapore
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitario Vall Dhebron
    Barcelona, 08035, Spain
  • Institut Catala Doncologia
    Barcelona, 08908, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Hm Madrid Sanchinarro
    Madrid, 28050, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, 28222, Spain
  • Clinica Universidad de Navarra Pamplona
    Pamplona, 31008, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Chi Mei Medical Center
    Tainan, 710, Taiwan
  • Sarah Cannon Research Institute Uk
    London, W1G 6AD, United Kingdom
  • Clatterbridge Cancer Centre
    Wirral, CH63 4JY, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jun 2020, 23 months.

Results were first posted in Sep 2023, 3 years 3 months after primary completion. A results delay was requested in Sep 2021.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 23 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2018
First posted
Feb 9, 2018
StartActual
Jul 3, 2018
Primary completionActual
Jun 18, 2020
CompletionActual
Jan 3, 2023
Results delay requested
Sep 10, 2021
Results first posted
Sep 21, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03427814
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Feb 9, 2018
Start date
Jul 3, 2018
Primary completion
Jun 18, 2020
Completion
Jan 3, 2023
Results posted
Sep 21, 2023
Last update
Oct 26, 2024

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pamiparib

Start the discussion